Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.55 |
| ▸ | CTSK | P43235 | 10/20 | 0.55 |
| ▸ | CTSB | P07858 | 4/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | P4HB | P07237 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938811 | 1.00 | CTSS (0.55) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL27094017 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL27094013 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL27093814 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL27093808 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL16510451 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL13340022 | 0.83 | CTSS (0.65) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL13128261 | 0.81 | CTSS (0.68) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3052728 | 0.80 | ACE (0.58) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3052733 | 0.80 | ACE (0.58) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398962-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY (CZ) | 2024-12-05 | — | — | US | disclosed |
| EP-4322961-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221490-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398962-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | GLUL, GLS, GRM2 | CTSS 999/4885CTSK 868/4885CTSB 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.